Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of LY06006 vs Prolia in Healthy Chinese Males
NCT04973722Phase 1Unknown
- Sponsor
- Luye Pharma Group
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMAB807 in osteoporosis (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Area Under the Curve from time zero to infinity at 168 days, Maximum Serum Concentration at 168 days and 4 more. Status: unknown.
02
Drugs
CMAB807
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04973722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973722.